Sandoz has delivered the first denosumab biosimilar launch in Canada, introducing its Jubbonti and Wyost rivals to Amgen’s Prolia and Xgeva.
Sandoz has debuted biosimilar competition to Amgen’s denosumab brands Prolia and Xgeva in Canada, introducing its Jubbonti and Wyost versions as “the first denosumab biosimilars available in Canada, reflecting the Sandoz purpose of pioneering access for patients.”
So far, Sandoz is the only company to have won Health Canada approval for a denosumab biosimilar.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
